{"total":254,"items":[{"description":"Improving treatment options for patients with hypervascular tumors","story":null,"hasStory":false,"investmentStartDate":"2025-01-01","investmentEndDate":null,"logo":null,"logoTint":"v1773366257/ptszkoxqgux3ncw6o6eo.png","name":"ABK Biomedical","sectors":[{"label":"Med Tech","value":"med-tech","icon":"v1525262465/qere41q1rt8k4vd8wmy6.svg","color":"#c3dbbc"}],"website":"https://abkbiomedical.com/","fundType":null,"exited":false},{"description":"Consulting orientated research and analytics, modelling, reporting and data management (Exited)","story":null,"hasStory":false,"investmentStartDate":"2008-12-17","investmentEndDate":null,"logo":"v1/products/absolutdata_AGZdz9W.jpg","logoTint":"v1530636221/bki9awz8uwo3ztutiaik.jpg","name":"AbsolutData","sectors":[{"label":"Enterprise","value":"enterprise","icon":"v1525262484/kbejrof0n7xnbhlc0ma4.svg","color":"#cac8ac"}],"website":"http://www.absolutdata.com/","fundType":null,"exited":false},{"description":"A global, clinical-stage immunotherapy company (NASDAQ: ADAG)","story":null,"hasStory":false,"investmentStartDate":"2025-01-01","investmentEndDate":null,"logo":null,"logoTint":"v1773634942/v2kfadlgs1or8xuu44ju.png","name":"Adagene","sectors":[{"label":"Pharma & Therapeutics","value":"pharma-therapeutics","icon":"v1525262373/q99muekslkuekst7qka7.svg","color":"#a7d6e3"}],"website":"https://www.adagene.com/zh/zhuye/","fundType":null,"exited":false},{"description":"Clinical-stage biopharmaceutical company.","story":null,"hasStory":false,"investmentStartDate":"2015-01-25","investmentEndDate":null,"logo":"v1/products/adaptimmune.jpg","logoTint":"v1530633899/xh6mx2ucvfrnbqcra2ab.jpg","name":"Adaptimmune","sectors":[{"label":"Pharma & Therapeutics","value":"pharma-therapeutics","icon":"v1525262373/q99muekslkuekst7qka7.svg","color":"#a7d6e3"}],"website":"http://www.adaptimmune.com/","fundType":null,"exited":false},{"description":"A biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics","story":null,"hasStory":false,"investmentStartDate":"2025-01-01","investmentEndDate":null,"logo":null,"logoTint":"v1773222307/lh5yqbfkfbpzwst0ipub.png","name":"Adcentrx Therapeutics","sectors":[{"label":"Pharma & Therapeutics","value":"pharma-therapeutics","icon":"v1525262373/q99muekslkuekst7qka7.svg","color":"#a7d6e3"}],"website":"https://www.adcentrx.com/","fundType":null,"exited":false},{"description":"Gene therapy company.","story":null,"hasStory":false,"investmentStartDate":"2020-06-03","investmentEndDate":null,"logo":null,"logoTint":"v1591196348/jo6432pd0mm0tvg2r76d.jpg","name":"Affinia Therapeutics","sectors":[{"label":"Pharma & Therapeutics","value":"pharma-therapeutics","icon":"v1525262373/q99muekslkuekst7qka7.svg","color":"#a7d6e3"}],"website":"https://www.affiniatx.com/","fundType":null,"exited":false},{"description":"Virtual credit card for mobile shopping in Indonesia.","story":null,"hasStory":false,"investmentStartDate":"2017-05-23","investmentEndDate":null,"logo":"v1/products/al.jpg","logoTint":"v1530633087/qc0ll2syowxmjcscnqxz.jpg","name":"Akulaku","sectors":[{"label":"Fintech","value":"fintech","icon":"v1525262430/hjqmieonc8ri9ngtodzj.svg","color":"#000000"}],"website":"https://www.akulaku.com/","fundType":null,"exited":false},{"description":"The world's best known e-commerce ecosystem providing C2C, B2C and B2B sales services.","story":{"url":"/api/stories/alibaba-the-story-of-a-generation","slug":"alibaba-the-story-of-a-generation","headline":"Alibaba: The story of a generation"},"hasStory":true,"investmentStartDate":"1999-09-12","investmentEndDate":null,"logo":"v1/products/alibaba_wuBYwN7.jpg","logoTint":"v1530621337/fpzdehy9pmgqma0rr0zq.jpg","name":"Alibaba","sectors":[{"label":"Consumer","value":"consumer","icon":"v1525262247/nicemn8wujh6rnofaolo.svg","color":"#f2c6a2"},{"label":"Enterprise","value":"enterprise","icon":"v1525262484/kbejrof0n7xnbhlc0ma4.svg","color":"#cac8ac"}],"website":"http://www.alibaba.com","fundType":null,"exited":false},{"description":"A biopharmaceutical company focused on innovative targeted radioligand therapies (RLTs)","story":null,"hasStory":false,"investmentStartDate":"2025-01-01","investmentEndDate":null,"logo":null,"logoTint":"v1773220772/anjzc7n8gvhrm7vj1bfa.png","name":"AlphaGen","sectors":[{"label":"Pharma & Therapeutics","value":"pharma-therapeutics","icon":"v1525262373/q99muekslkuekst7qka7.svg","color":"#a7d6e3"}],"website":"https://www.alphagentx.com/","fundType":null,"exited":false},{"description":"A biotechnology company developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes","story":null,"hasStory":false,"investmentStartDate":"2025-01-01","investmentEndDate":null,"logo":null,"logoTint":"v1773223056/ffh8ybyjugzld7ft2xs6.png","name":"Alternative Bio","sectors":[{"label":"Pharma & Therapeutics","value":"pharma-therapeutics","icon":"v1525262373/q99muekslkuekst7qka7.svg","color":"#a7d6e3"}],"website":"","fundType":null,"exited":false}],"_pagination":{"current":1,"total":26,"next":"https://eightroads.com/api/companies?language=en&page=2","previous":null,"limit":10}}